? DESCRIPTION (provided by applicant): New therapies are urgently needed for Acute Myelogenous Leukemia (AML). Treatment-resistant AML cells are evidently protected within bone marrow endosteal niches. This proposal is designed to provide groundwork for the development of new therapies aimed at inhibiting the cellular mechanisms of the bone marrow microenvironment that protect AML cells. We recently found that differentiating osteoblasts, but not the osteoprogenitors or terminally-differentiated osteocytes, are capable of protecting AML cells from apoptosis including that induced by SDF-1 (CXCL12) secreted by other cells in the bone marrow microenvironment. Additionally, our preliminary data indicates that differentiating osteoblasts also protect AML cells from chemotherapeutic-induced apoptosis. Interestingly, our results indicate that an early stage of differentiation of osteoprogenitors towards osteoblasts is crucial to permit these cells to protect AML cells. Inhibition of the specific stage(s) of osteoblat differentiation capable of protecting AML cells from SDF-1- or chemotherapeutic-induced apoptosis might enhance the efficacy of current therapies of AML. Unfortunately, this protective stage of osteoblast differentiation is not clearly defined at present. Here, we propos to use our in vitro co-culture systems and mouse models of AML to test our hypothesis that inhibiting osteoblast differentiation will significantly impair the ability of the endosteal bone marrow niche to protect AML cells. Our Aims are to 1) Disrupt specific stages of osteoblast differentiation via characterized genetic alterations in order to identify the particular stage(s) f osteoblast development capable of protecting AML cells in in vitro co-culture models of the bone marrow, and to 2) Determine the survival rate and localization of AML cells in mouse bone marrow microenvironments deficient in osteoblast differentiation, and assess the effects on the severity of AML disease and the rate of relapse in these animals. Combined, these studies will test our hypothesis and identify the particular stage(s) of osteoblast differentiation that mediate protection of AML cells from SDF-1- and chemotherapeutic-induced apoptosis.
|Effective start/end date||4/23/15 → 3/31/17|
- National Institutes of Health: $207,495.00
- National Institutes of Health: $172,913.00
Acute Myeloid Leukemia
Bone Marrow Cells